Nicotinamide Riboside in Hospitalized Patients

Overview

Patients will receive oral nicotinamide riboside or placebo and clinical and paraclinical outcome will be determined

Full Title of Study: “Shorter Recovery Time After Critical Illness”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Supportive Care
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 1, 2022

Detailed Description

Patients experiencing acute illness will often have a prolonged recovery time. The cause of this is unknown, but certain factors, like age, duration, and graveness of the illness, is associated with prolonged recovery. In this study, we will investigate whether nicotinamide riboside can shorten the recovery phase and improve outcome after acute illness.

Interventions

  • Drug: Nicotinamide riboside
    • Nicotinamide riboside in different doses
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: Nicotinamide riboside 250 mg
    • One capsule of 250 mg each morning for three months
  • Experimental: Nicotinamide riboside 500 mg
    • One capsule of 250 mg each morning and afternoon for three months
  • Experimental: Nicotinamide riboside 1000 mg
    • Two capsules of 250 mg each morning and afternoon for three months
  • Experimental: Nicotinamide riboside 2000 mg
    • Four capsules of 250 mg each morning and afternoon for three months
  • Placebo Comparator: Placebo for 250 mg nicotinamide riboside
    • One capsule each morning for three months
  • Placebo Comparator: Placebo for 500 mg nicotinamide riboside
    • One capsule each morning and afternoon for three months
  • Placebo Comparator: Placebo for 1000 mg nicotinamide riboside
    • Two capsules each morning and afternoon for three months
  • Placebo Comparator: Placebo for 2000 mg nicotinamide riboside
    • Four capsules each morning and afternoon for three months

Clinical Trial Outcome Measures

Primary Measures

  • Length of stay from randomization to discharge from hospital to home or to an institution with a lower care level than a hospital for instance a long term care facility.
    • Time Frame: Up to 90 days
    • Days

Secondary Measures

  • Time to normalization of urine production
    • Time Frame: Up to 90 days
    • Measured in ml/hour
  • Mortality
    • Time Frame: At 90 days, 65 weeks and 10 years
    • Number of deaths
  • Length of stay from randomization to medically fit for discharge from hospital to home or to an institution with a lower care level than a hospital for instance a long term care facility.
    • Time Frame: Up to 90 days
    • Days
  • Time to normalization of blood pressure
    • Time Frame: Up to 90 days
    • Hours/days
  • Change in blood pressure during the study period
    • Time Frame: Baseline and 90 days and 65 weeks
    • mmHg
  • Days on respiratory support
    • Time Frame: Up to 90 days
    • Days
  • Number of days with temperature above 38 at any point from inclusion to discharge.
    • Time Frame: Up to 90 days
    • Days
  • Number of days with temperature above 38 at any point from inclusion to discharge divided on number of days from inclusion to discharge
    • Time Frame: 90 days
    • Number of days
  • Duration of stay in ICU after randomization
    • Time Frame: Up to 90 days
    • Days
  • Number of newly diagnosed infections with identified agent from inclusion to end of trial
    • Time Frame: 90 days and 65 weeks
    • Number
  • Number of newly diagnosed infections from inclusion to end of trial
    • Time Frame: 90 days and 65 weeks
    • Number
  • Days on antibiotics from inclusion to end of trial
    • Time Frame: 90 days and 65 weeks
    • Days
  • Days from inclusion to first antibiotic free day
    • Time Frame: Up to 90 days
    • Days
  • Highest CRP from inclusion to end of trial
    • Time Frame: Up to 90 days
    • CRP value
  • Changes in DNA methylation clocks
    • Time Frame: At baseline, 90 days and 65 weeks.
    • Changes in the published DNA methylation clocks by Steve Horvath (Multi tissue, 2013, Skin and Blood, 2018, PhenoAge 2017, GrimAge 2018, telomere length 2019) and Hannum (Hannum clock 2013), Yan Zhang (continous Zhang score, 2017), AgeLab01 (Poster, Gordon Conference, Biology of Aging, July, 2019). All clocks are algorithms based on the Illumina “EPIC” DNA methylation BeadArray.
  • Changes in DNA methylation measured by the Illumina DNA methylation BeadArray
    • Time Frame: At baseline, 90 days and 65 weeks.
    • Methylation sites (CpG sites) that are differentially changed in the intervention groups compared to the placebo group(s) over the studied time period. Correction for multiple testing will be done.
  • Change in quality of life
    • Time Frame: 14 days prior to admission, baseline, 90 days and 65 weeks
    • EQ-5D-5L (Quality of life instrument developed by the EuroQol group). Scores ranging from 11111 (full health) to 33333/55555 (worst health).
  • Change in Katz activities of daily living
    • Time Frame: 14 days prior to admission, baseline, 90 days and 65 weeks
    • Measured at pre-baseline (-14 days), 90 days and 65 weeks. Score 0-6 describing increasing levels of independency.
  • Change in MoCA
    • Time Frame: Day 7, 90 and at 65 weeks
    • MoCA (Montreal Cognitive Assessment): Score 0-30. Score of 26 or over is considered normal. Lower scores indicates cognitive impairment.
  • Trail Making Test A
    • Time Frame: Day 7, 90 and at 65 weeks
    • Time in seconds
  • Trail Making Test B
    • Time Frame: Day 7, 90 and at 65 weeks
    • Time in seconds
  • Change in forward and backward recall
    • Time Frame: Day 7, 90 and at 65 weeks
    • Test result change over the study period
  • Change in NEWS score from -4 hours to 0 hours before first tablet to 1,3, 7 days after first capsule
    • Time Frame: Four hours before the first administration of NR, at administration of the first capsule and 1, 3 an 7 days after administration of first capsule
    • NEWS (National Early Warning Score): Score 0-20. High scores indicate high degree of illness.
  • Change in ECOG status
    • Time Frame: 14 days prior to admission, baseline, day 7, day 90 and week 65
    • Eastern Cooperative Oncology Group (0-5, higher is worse)
  • Change in GSC
    • Time Frame: Day 1, 3 and 7
    • Glasgow Coma Scale
  • Change in 4 meter walking test
    • Time Frame: Baseline, day 7, day 90 and week 65
    • Time in seconds
  • Change in clinical Frailty Score
    • Time Frame: Baseline, day 7, day 90 and week 65
    • Time in seconds
  • Change in grip strength over three months
    • Time Frame: Baseline, day 7, day 90 and at 65 weeks
    • Kg measured with a handheld dynamometer
  • Change in CAM-ICU
    • Time Frame: Baseline and day 1,3,7, and every week of hospitalization in ICU
    • CAM-ICU (Confusion Assessment Method for the ICU): Algorithm of Yes/No questions.
  • Changes in hearing
    • Time Frame: At baseline, 7 and 90 days and 65 weeks
    • Audiogram
  • Change in left ventricular ejection fraction
    • Time Frame: Baseline, day 7 and at 90 days
    • Measured with echocardiography
  • Mitochondrial biogenesis – Respiratory Chain Enzyme Analysis
    • Time Frame: Baseline and 90 days
    • Change from baseline in mitochondrial function at the start and end of the 4 weeks of NR treatment (Respiratory chain enzyme analysis)
  • Change in mitochondrial biogenesis – mitochondrial DNA quantification
    • Time Frame: Baseline to 90 days
    • Change from baseline in the amount of mitochondrial DNA at the start and end of the 90 days of NR treatment (mtDNA quantification)
  • Change in NAD+ (nicotinamide adenosine dinucleotide) and related metabolite blood levels
    • Time Frame: Baseline, day 7 and day 90
    • Blood samples will be analysed using high performance liquid chromatography-mass spectroscopy and kit-based analysis for levels of NAD+ and related metabolites including: nicotinamide-adenine dinucleotide phosphate, nicotinic acid adenine dinucleotide, nicotinamide, and nicotinamide mononucleotide.
  • Number of readmissions to hospital
    • Time Frame: Up to 90 days
    • Number
  • Safety – change in blood analytes
    • Time Frame: Up to 90 days
    • Change from baseline in safety blood analyte levels – Sodium potassium phosphate urea creatinine albumin bilirubin carbamide CRP ALP AST ALT LT GT amylase Mg ferritin hemoglobin leucocytes with subgroups thrombocytes Ca INR PH(venous) HCO3(venous) ProBNP HbA1c TSH fT4 folate homocysteine cholesterol LDL HDL CKMB TNT
  • Safety – adverse events
    • Time Frame: Up to 90 days
    • Adverse events classified according to CTCAE

Participating in This Clinical Trial

Inclusion Criteria

1. Adults > 18 years old, admitted to hospital with tissue damage, can be included when they are considered medically stable though still expected to remain hospitalized for at least 7 more days (from inclusion). 2. Preferably: Previously included in the Janus Cohort or any other cohort or study with stored biological samples. Exclusion Criteria:

1. Allergy to NR or ingredients in capsules or placebo. 2. Patients expected to pass away within 90 days. 3. Patients unable to give their consent 4. Unstable patients: i. Uncontrolled infection (clinical septicaemia, inadequate response to treatment, inadequate control of source of infection or at treating physician's discretion). ii. Mean arterial pressure <70 mm Hg and symptoms of hypotension. iii. Patients requiring dialysis at the time of inclusion or glomerular filtration rate <40 iv. Liver failure with Child-Pugh class B or C or any class associated with hepatic encephalopathy (any grade), alanin aminotransferase or aspartate aminotransferase >3 times upper limit v. Moderate to severe peripheral oedema and/or pulmonary oedema, any unstable cardiac rhythm, myocardial infarction with peak TNT >300 past week. Signs of elevated intracranial pressure (headache, vomiting and depressed global consciousness in conjunction with focal neurological signs, papilledema, spontaneous periorbital bruising and a triad of bradycardia, respiratory depression and hypertension). vi. Arterial pH <7.30 or >7.50 vii. Serum potassium under 3,2 or over 5 mmol/L. 5. Pregnancy or breastfeeding * 6. Any cancer not in full remission for >10 years 7. Use of St John's Wort based supplements during the past 30 days 8. Patient has undergone solid organ transplantation 9. Participation in any clinical trial with unknown medications 10. Major gastrointestinal or other internal bleeding past week 11. Logistical challenges after discharge. Patient must be able to attend follow up. 12. The treating physician considers the patient unfit or unable to participate. *All fertile women must have a human chorionic gonadotropin test.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Oslo University Hospital
  • Collaborator
    • ChromaDex, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Arne Vasli Lund Søraas, Principal Investigator – Oslo University Hospital
  • Overall Official(s)
    • Arne Søraas, PhD, Principal Investigator, Oslo University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.